Recombinant Protein CDMOs — Ranked by Signal Score · 2026
48
CDMOs tracked
14
Fully scored
8
With FDA records
23
FDA inspections
99
EMA/MHRA GMP certs
2
Warning letters
Recombinant protein CDMOs make therapeutic proteins, enzymes, and growth factors using microbial (E. coli, yeast) or mammalian (CHO) expression. Choice of host turns on post-translational modification needs, scale economics, and downstream-purification complexity.
Selecting a recombinant protein CDMO turns on host-system experience, validated bioreactor scale, downstream purification and analytics, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 7 NAI (no action), 14 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: Germany (29), United States (22), Denmark (18), UNITED KINGDOM (11), UNITED STATES (9).
Last updated 2026-08-22. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
AG
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
|
80.6 | 99.9 | 2 insp · 23 GMP | Available | 2 programs |
| 2 |
Lonza
Basel, Switzerland
|
78.2 | 95.1 | 2 insp · 8 GMP | — | 1 programs |
| 3 |
PB
Pharmaron Biologics
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
|
86.9 | 100.0 | 3 insp · 0 GMP | Available | 0 programs |
| 4 |
KB
KBI Biopharma
Durham, NC · Boulder, CO
|
83.5 | 100.0 | 1 insp · 1 GMP | Limited | 0 programs |
| 5 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 6 |
WK
Wacker Biotech
Jena, DE · Amsterdam, NL · San Diego, CA
|
81.6 | 100.0 | 0 insp · 13 GMP | — | 0 programs |
| 7 |
NW
Northway Biotech
Vilnius, LT; Waltham (MA), USA
|
80.8 | 100.0 | 0 insp · 8 GMP | Available | 0 programs |
| 8 |
RB
Rentschler Biopharma
Laupheim, Germany
|
79.9 | 99.3 | 1 insp · 2 GMP | — | 0 programs |
| 9 |
Catalent
Bagsværd, Denmark (operating under Novo Holdings; legacy US operations headquartered in Somerset, NJ)
|
76.5 | 79.3 | 12 insp · 35 GMP | — | 0 programs |
| 10 |
CA
Catalent (Novo Holdings)
Harmans, MD · Gosselies, BE
|
75.1 | 79.3 | 1 insp · 0 GMP | Available | 0 programs |
| 11 |
LZ
Lonza Biologics
Houston, TX · Portsmouth, NH · Geleen, NL · Basel, CH
|
72.8 | 95.1 | 1 insp · 0 GMP | Limited | 0 programs |
| 12 |
SB
Samsung Biologics
Incheon, South Korea, Rockville, Maryland, USA
|
61.5 | — | — | Available | 0 programs |
| 13 |
Cytovance Biologics
Oklahoma City, OK
|
61.5 | — | — | Available | 0 programs |
| 14 |
BN
Bionova Scientific
Fremont, CA
|
59.0 | — | — | — | 0 programs |
| — |
3P Biopharmaceuticals (now 3PBIOVIAN)
Pamplona-Noáin, Spain
|
Profiled | — | — | — | 0 programs |
| — |
BioCina
Adelaide, Australia
|
Profiled | — | — | — | 0 programs |
| — |
Icosagen
Tartu, Estonia
|
Profiled | — | — | — | 0 programs |
| — |
Altruist Biologics
Suzhou, China
|
Profiled | — | — | Available | 0 programs |
| — |
Olon Group
Rodano (Milan), Italy
|
Profiled | — | — | — | 0 programs |
| — |
53Biologics
Boecillo (Valladolid), Spain
|
Profiled | — | — | — | 0 programs |
| — |
Mabion S.A.
Konstantynów Łódźki, Poland
|
Profiled | — | — | — | 0 programs |
| — |
EirGenix
Zhubei City, Taiwan
|
Profiled | — | — | — | 0 programs |
| — |
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Biological E. Limited (BioE)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
Kemwell Biopharma
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
Kemwell Biopharma, Bangalore
Bengaluru, India
|
Profiled | — | — | — | 0 programs |
| — |
BE Biosol (formerly SGI Pharma / Biological E, Samirpet)
Hyderabad, India
|
Profiled | — | — | — | 0 programs |
| — |
AsymBio
Shanghai, China
|
Profiled | — | — | — | 0 programs |
| — |
Advanced BioScience Laboratories, Inc. (ABL Inc.)
Rockville, MD
|
Profiled | — | — | — | 0 programs |
| — |
Biologics / mAb Programs — Host Cell Protein (HCP) & Impurity-Driven Failures
N/A — Industry-Wide Pattern
|
Profiled | — | — | — | 0 programs |
| — |
LFB Biomanufacturing
Alès, France
|
Profiled | — | — | — | 0 programs |
| — |
Scorpius BioManufacturing
San Diego, CA
|
Profiled | — | — | — | 0 programs |
| — |
iBio (FastPharming / iBio CDMO LLC)
Bryan, TX (historic CDMO facility); current corporate pivot to San Diego, CA
|
Profiled | — | — | — | 0 programs |
| — |
Kentucky Bioprocessing (KBP)
Owensboro, KY
|
Profiled | — | — | — | 0 programs |
| — |
IDT Biologika GmbH
Dessau-Roßlau, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)
Hangzhou, China
|
Profiled | — | — | — | 0 programs |
| — |
Richter-Helm / Gedeon Richter Biologics (Mammalian DP complement)
Budapest, Hungary
|
Profiled | — | — | — | 0 programs |
| — |
Pharmaron Biologics (Liverpool)
Liverpool, United Kingdom
|
Profiled | — | — | — | 0 programs |
| — |
Chime Biologics
Wuhan, China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics Co., Ltd.
Foshan (Shunde District), China
|
Profiled | — | — | — | 0 programs |
| — |
Canton Biologics
Guangzhou, China
|
Profiled | — | — | — | 0 programs |
| — |
Wheeler Bio
Oklahoma City, OK
|
Profiled | — | — | — | 0 programs |
| — |
Sanofi (Genzyme / Sanofi Manufacturing)
Paris, France
|
Profiled | — | — | — | 0 programs |
| — |
Novasep
Lyon, France
|
Profiled | — | — | — | 0 programs |
| — |
CSIRO National Vaccine and Therapeutics Laboratory
Clayton, Victoria, Australia
|
Profiled | — | — | — | 0 programs |
| — |
National Biologics Facility (NBF)
Brisbane, Queensland, Australia
|
Profiled | — | — | — | 0 programs |
| — |
Zencore Biologics
Shanghai, China (R&D facility: Maryland, USA)
|
Profiled | — | — | — | 0 programs |
| — |
Enzene Biosciences
Pune, India
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Recombinant Proteins CDMO
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
Recombinant Proteins CDMOs — Frequently Asked Questions
Who are the top Recombinant Proteins CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Recombinant Proteins CDMOs include AGC Biologics, Lonza, Pharmaron Biologics. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Recombinant Proteins CDMOs have FDA inspection records?
CDMO Signal tracks 8 Recombinant Proteins CDMOs with FDA inspection records and 99 EMA/MHRA GMP certificates across the group.
What should I look for in a recombinant protein CDMO?
Confirm expression-host experience for your target (microbial vs mammalian), validated bioreactor scale, a strong downstream-purification platform, qualified analytics, and a clean FDA and EMA/MHRA record.
How is a recombinant protein CDMO different from a mAb CDMO?
There's significant overlap — mAbs are recombinant proteins. But mAb CDMOs are typically optimized for CHO-based platform processes, while general recombinant protein CDMOs handle a wider range of hosts and non-mAb formats (enzymes, growth factors, complex non-glycoproteins).
Related modalities